HuGE Literature Finder
Records
1
-
10
| Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer. Cancer 2017 Aug 123 (15): 2936-2944. Tarhini Ahmad A, Rafique Imran, Floros Theofanis, Tran Phu, Gooding William E, Villaruz Liza C, Burns Timothy F, Friedland David M, Petro Daniel P, Farooqui Mariya, Gomez-Garcia Jose, Gaither-Davis Autumn, Dacic Sanja, Argiris Athanassios, Socinski Mark A, Stabile Laura P, Siegfried Jill |
| Plasma T790M and HGF as potential predictive markers for EGFR-TKI re-challenge. Oncology letters 2017 Jun 13 (6): 4939-4946. Nakamura Tomomi, Watanabe Naomi, Sato Akemi, Komiya Kazutoshi, Umeguchi Hitomi, Hosomi Toshiya, Hirai Mitsuharu, Sueoka Eisaburo, Kimura Shinya, Sueoka-Aragane Nao |
| Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma. Medical science monitor : international medical journal of experimental and clinical research 2016 22 276-83. He Yayi, Wang Yan, Boyle Theresa, Ren Shengxiang, Chan Dan, Rivard Chris, Li Xuefei, Li Jiayu, Zhou Caicun, Hirsch Fred |
| Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib. ESMO open 2016 1 (4): e000063. Azuma Koichi, Hirashima Tomonori, Yamamoto Nobuyuki, Okamoto Isamu, Takahashi Toshiaki, Nishio Makoto, Hirata Taizo, Kubota Kaoru, Kasahara Kazuo, Hida Toyoaki, Yoshioka Hiroshige, Nakanishi Kaoru, Akinaga Shiro, Nishio Kazuto, Mitsudomi Tetsuya, Nakagawa Kazuhi |
| Clinical usefulness of gefitinib for non-small-cell lung cancer with a double epidermal growth factor receptor mutation. Molecular and clinical oncology 2015 Mar 3 (2): 329-333. Oikawa Takefumi, Ohira Tatsuo, Otani Keishi, Hagiwara Masaru, Konaka Chimori, Ikeda Norihi |
| A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903). Lung cancer (Amsterdam, Netherlands) 2014 Nov 86 (2): 195-200. Matsumoto Yoshifumi, Maemondo Makoto, Ishii Yoshiki, Okudera Koichi, Demura Yoshiki, Takamura Kei, Kobayashi Kunihiko, Morikawa Naoto, Gemma Akihiko, Ishimoto Osamu, Usui Kazuhiro, Harada Masao, Miura Satoru, Fujita Yuka, Sato Ikuro, Saijo Yasuo, |
| c-Met Mutational Analysis in the Sema and Juxtamembrane Domains in Small-Cell-Lung-Cancer. Translational oncogenomics 2013 5 1 11-8. de Aguirre Itziar, Salvatierra Alejandro, Font Albert, Mate Jose Luis, Perez Maria, Botia Monica, Taron Miquel, Rosell Rafa |
| Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI. Anticancer research 2012 Sep 32 (9): 3785-90. Uramoto Hidetaka, Yamada Tadaaki, Yano Seiji, Kondo Nobuyuki, Hasegawa Seiki, Tanaka Fumihi |
| Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2011 Nov 74 (2): 293-9. Han Ji-Youn, Kim Jin Young, Lee Suk Hyung, Yoo Nam Jin, Choi Byung G |
| Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer science 2008 Nov 99 (11): 2280-5. Okuda Katsuhiro, Sasaki Hidefumi, Yukiue Haruhiro, Yano Motoki, Fujii Yoshita |
- Page last reviewed:Feb 1, 2023
- Page last updated:Feb 03, 2023
- Content source: